EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives

Geofanny Facicilia, Cynthia Retna Sartika, Yuni Elsa Hadisaputri iD, Tina Rostinawati

Cells · 06.11.2026 · 15 (21) · 2029

DOI: 10.3390/cells15212029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.11.2026. Verfasst von Geofanny Facicilia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, CRISPR-Cas Systems, Gene Editing, Translational Research, Biomedical. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Padjadjaran, PT Prodia Utama.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal stem cells (MSCs) are promising platforms for regenerative and immunomodulatory therapies, but their clinical performance is limited by donor heterogeneity, variable potency, and limited persistence. CRISPR-based engineering provides programmable approaches to modify MSC function through genome editing and transcriptional regulation. This review examines CRISPR/Cas9-mediated knockout and knock-in, dCas9-based transcriptional regulation, and emerging base-, prime-, and epigenome-editing technologies for MSC engineering. These approaches can enhance survival and stress resistance, homing and tissue retention, paracrine and extracellular vesicle activity, immunomodulation, immune compatibility, and lineage-associated functions. Key translational challenges include efficient delivery, engineered-population heterogeneity, genomic safety, immunogenicity, phenotypic stability, scalable manufacturing, and mechanism-linked potency assessment. The appropriate engineering strategy should therefore be selected according to the intended therapeutic mechanism and product development requirements. Clinical translation will ultimately depend on demonstrating reproducible functional enhancement, manufacturing consistency, genomic and phenotypic stability, and validated therapeutic potency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsCRISPR-Cas SystemsGene EditingTranslational Research, BiomedicalHumansAnimalsEpigenome Editing

Stichwörter der Autor:innen

CRISPR activationCRISPR/Cas9cell therapyfunctional potencygene engineeringmesenchymal stem cells

Autor:innen und Institutionen

  • Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor 45363, Indonesia.
  • Prodia StemCell Indonesia, DKI Jakarta, Jakarta 13410, Indonesia.

ORCID-Profile: Yuni Elsa Hadisaputri

Förderung

  • Universitas Padjadjaran
  • PT Prodia Utama

Zitieren

APA

Facicilia, G., Sartika, C. R., Hadisaputri, Y. E., & Rostinawati, T. (2026). CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives. Cells, 15(21), 2029. https://doi.org/10.3390/cells15212029

Vancouver

Facicilia G, Sartika CR, Hadisaputri YE, Rostinawati T. CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives. Cells. 2026;15(21):2029. doi:10.3390/cells15212029

BibTeX
@article{Facicilia2026,
  author = {Facicilia, Geofanny and Sartika, Cynthia Retna and Hadisaputri, Yuni Elsa and Rostinawati, Tina},
  title = {CRISPR-Based Engineering of Mesenchymal Stem Cells: Functional Enhancement, Translational Challenges, and Clinical Perspectives},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {2029},
  doi = {10.3390/cells15212029}
}
Kostenlos starten →